What is Abionic?
Founded in 2010, Abionic has established itself as a leader in the rapid diagnostic sector, earning recognition as the Swiss MedTech of the Year in 2023. The company's core innovation, the abioSCOPE, utilizes a single drop of blood to deliver precise diagnostic data within minutes. This point-of-care solution is specifically engineered to integrate into high-pressure clinical environments, such as emergency rooms and intensive care units, where it facilitates the rapid identification of critical conditions like sepsis. By bridging the gap between traditional laboratory testing and immediate clinical decision-making, Abionic is effectively enhancing diagnostic efficiency and improving patient outcomes on a global scale.
How much funding has Abionic raised?
Abionic has raised a total of $7.7M across 2 funding rounds:
Series A
$3.7M
Series B
$4M
Series A (2012): $3.7M, investors not publicly disclosed
Series B (2014): $4M led by Drexel Morgan & Co and BlueOcean Ventures SA
Key Investors in Abionic
Drexel Morgan & Co
Drexel Morgan Capital Advisers Inc is a firm operating within the investment banking sector, providing financial advisory and capital support to growing enterprises.
BlueOcean Ventures SA
BlueOcean Ventures is a specialized investment firm focused on early-stage medical device and life science companies, offering both financial backing and strategic mentorship.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Abionic?
With the support of its latest strategic investment, Abionic is set to accelerate its international market penetration and further refine its diagnostic pipeline. The company's roadmap focuses on deepening the integration of the abioSCOPE into existing hospital infrastructure, thereby streamlining the diagnostic process for healthcare professionals. As the firm continues to scale, the focus will likely shift toward expanding its portfolio of diagnostic assays and strengthening its presence in key global markets. This strategic growth trajectory is supported by a robust network of investors who provide both the financial resources and the industry expertise necessary to navigate the complex regulatory and commercial landscapes of the medical device industry.
See full Abionic company page
